Skip to Main Content
TABLE 1

Study Characteristics

Author, yCountryPerspectiveType of AnalysisOutcome MeasurePopulationTime HorizonDiscount RateIndustry Funding
Banerji et al24 2016 Canada Payer CEA Cost per HA Term infants 6 mo N/A Abbott and MedImmune, LLC (grants) 
Bentley et al35 2013 United Kingdom Payer CUA Cost per QALY Preterm infants with CHD, and CLD Lifetime 3.5% AbbVie 
Blanken et al46 2018 Netherlands Societal CUA Cost per QALY Preterm infants 1 y N/A Unknown: grants for investigator-initiated studies from MedImmune and AbbVie, including the MAKI trial, from which data for this CEA were derived 
Chirico et al47 2009 Italy Payer CUA Cost per QALY Preterm infants with BPD Lifetime 3% Abbott 
Elhassan et al44 2006 United States Societal CUA; CBA Cost per QALY Preterm infants without CLD 8 y 3% None 
Hampp et al48 2011 United States Payer CEA Cost per HA Preterm and term infants (both with and without CHD and CLD) NR NR None 
Harris et al49 2011 Canada Societal CEA; CBA Cost per day of HA Infants with CHD 5 ya NR Unknown: honorarium (<$1000) from Abbott Laboratories 
Hascoet et al50 2008 France Societal (BC) and payer CEA; CBA Cost per LYG Preterm infants with CHD or BPD Lifetime 3% Abbott France 
Lofland et al45 2000 United States Payer CEA Cost per RSV infection avoided Preterm infants with CLD 6 mo N/A MedImmune, LLC 
Mahadevia et al52 2012 United States Societal CUA Cost per QALY Preterm infants Lifetime 3% MedImmune, LLC 
McGirr et al25 2017 Canada Payer CUA Cost per QALY Term infants with cystic fibrosis Lifetime 5% None 
Neovius et al26 2011 Sweden Societal CUA Cost per QALY Preterm infants Lifetime 3% Abbott Scandinavia 
Nuijten et al30 2009 Germany Societal (BC) and payer CUA Cost per QALY Infants with CHD Lifetime 5% Abbott 
Nuijten et al29 2009 Netherlands Payer (BC) and societal CUA Cost per QALY Preterm infants with BPD and CHD Lifetime 4%, 1.5%b Abbott GmbH & Co KG (Ludwigshafen, Germany) 
Nuijten et al28 2010 Spain Payer (BC) and societal CUA Cost per QALY Preterm infants Lifetime 3% Abbott GmbH & Co KG (Ludwigshafen, Germany) 
Nuijten et al27 2007 United Kingdom Payer (BC) and societal CUA Cost per QALY; cost per HA Preterm infants with BPD and CHD Lifetime 3.5% Abbott GmbH & Co KG (Ludwigshafen, Germany) 
Resch et al31,32 2008, 2012 Austria Payer (BC) and societal CUA Cost per QALY Preterm infants with BPD and CHD Lifetime 5% None 
Rietveld et al33 2010 Netherlands Societal CEA Cost per HA Preterm infants with BPD 1 y N/A None 
Roeckl-Wiedmann et al34 2003 Germany Societal CEA Cost per HA Preterm infants with risk factors 1 y N/A Abbott Laboratories, Germany 
Salinas-Escudero et al36 2012 Mexico Payer CUA Cost per QALY Preterm infants Lifetime 3% Abbott Laboratories of Mexico 
Sanchez-Luna et al37 2017 Spain Payer (BC) and societal CUA Cost per QALY Preterm infants with risk factors 6 y 3% None 
Schmidt et al38 2017 Spain Societal CUA Cost per QALY Infants with CHD Lifetime 3% AbbVie (grant) 
Smart et al39,51 2010 Canada Payer (BC) and societal CUA Cost per QALY Preterm infants with risk factors Lifetime 5% Unknown: financial and other relationships with Abbott but not funded for this study 
Tam et al40 2009 Canada Payer (BC) and societal CUA Cost per QALY NR Lifetime 5% Abbott Laboratories and Abbott International (grant) 
Vogel et al41 2002 New Zealand Societal CEA; CBA Cost per case averted Preterm infants with CLD 3 ya NR Abbott (grant) 
Wang et al14 2008 United Kingdom Payer (BC) and societal CUA Cost per QALY Preterm infants with BPD, CHD, or CLD; term infants with risk factors Lifetime 3.5% None 
Weiner et al42 2012 United States Societal CUA Cost per QALY Preterm infants with risk factors Lifetime 3% MedImmune, LLC 
Yount et al43 2004 United States Societal CUA; CBA Cost per QALY Infants with CHD Lifetime 3% None 
Author, yCountryPerspectiveType of AnalysisOutcome MeasurePopulationTime HorizonDiscount RateIndustry Funding
Banerji et al24 2016 Canada Payer CEA Cost per HA Term infants 6 mo N/A Abbott and MedImmune, LLC (grants) 
Bentley et al35 2013 United Kingdom Payer CUA Cost per QALY Preterm infants with CHD, and CLD Lifetime 3.5% AbbVie 
Blanken et al46 2018 Netherlands Societal CUA Cost per QALY Preterm infants 1 y N/A Unknown: grants for investigator-initiated studies from MedImmune and AbbVie, including the MAKI trial, from which data for this CEA were derived 
Chirico et al47 2009 Italy Payer CUA Cost per QALY Preterm infants with BPD Lifetime 3% Abbott 
Elhassan et al44 2006 United States Societal CUA; CBA Cost per QALY Preterm infants without CLD 8 y 3% None 
Hampp et al48 2011 United States Payer CEA Cost per HA Preterm and term infants (both with and without CHD and CLD) NR NR None 
Harris et al49 2011 Canada Societal CEA; CBA Cost per day of HA Infants with CHD 5 ya NR Unknown: honorarium (<$1000) from Abbott Laboratories 
Hascoet et al50 2008 France Societal (BC) and payer CEA; CBA Cost per LYG Preterm infants with CHD or BPD Lifetime 3% Abbott France 
Lofland et al45 2000 United States Payer CEA Cost per RSV infection avoided Preterm infants with CLD 6 mo N/A MedImmune, LLC 
Mahadevia et al52 2012 United States Societal CUA Cost per QALY Preterm infants Lifetime 3% MedImmune, LLC 
McGirr et al25 2017 Canada Payer CUA Cost per QALY Term infants with cystic fibrosis Lifetime 5% None 
Neovius et al26 2011 Sweden Societal CUA Cost per QALY Preterm infants Lifetime 3% Abbott Scandinavia 
Nuijten et al30 2009 Germany Societal (BC) and payer CUA Cost per QALY Infants with CHD Lifetime 5% Abbott 
Nuijten et al29 2009 Netherlands Payer (BC) and societal CUA Cost per QALY Preterm infants with BPD and CHD Lifetime 4%, 1.5%b Abbott GmbH & Co KG (Ludwigshafen, Germany) 
Nuijten et al28 2010 Spain Payer (BC) and societal CUA Cost per QALY Preterm infants Lifetime 3% Abbott GmbH & Co KG (Ludwigshafen, Germany) 
Nuijten et al27 2007 United Kingdom Payer (BC) and societal CUA Cost per QALY; cost per HA Preterm infants with BPD and CHD Lifetime 3.5% Abbott GmbH & Co KG (Ludwigshafen, Germany) 
Resch et al31,32 2008, 2012 Austria Payer (BC) and societal CUA Cost per QALY Preterm infants with BPD and CHD Lifetime 5% None 
Rietveld et al33 2010 Netherlands Societal CEA Cost per HA Preterm infants with BPD 1 y N/A None 
Roeckl-Wiedmann et al34 2003 Germany Societal CEA Cost per HA Preterm infants with risk factors 1 y N/A Abbott Laboratories, Germany 
Salinas-Escudero et al36 2012 Mexico Payer CUA Cost per QALY Preterm infants Lifetime 3% Abbott Laboratories of Mexico 
Sanchez-Luna et al37 2017 Spain Payer (BC) and societal CUA Cost per QALY Preterm infants with risk factors 6 y 3% None 
Schmidt et al38 2017 Spain Societal CUA Cost per QALY Infants with CHD Lifetime 3% AbbVie (grant) 
Smart et al39,51 2010 Canada Payer (BC) and societal CUA Cost per QALY Preterm infants with risk factors Lifetime 5% Unknown: financial and other relationships with Abbott but not funded for this study 
Tam et al40 2009 Canada Payer (BC) and societal CUA Cost per QALY NR Lifetime 5% Abbott Laboratories and Abbott International (grant) 
Vogel et al41 2002 New Zealand Societal CEA; CBA Cost per case averted Preterm infants with CLD 3 ya NR Abbott (grant) 
Wang et al14 2008 United Kingdom Payer (BC) and societal CUA Cost per QALY Preterm infants with BPD, CHD, or CLD; term infants with risk factors Lifetime 3.5% None 
Weiner et al42 2012 United States Societal CUA Cost per QALY Preterm infants with risk factors Lifetime 3% MedImmune, LLC 
Yount et al43 2004 United States Societal CUA; CBA Cost per QALY Infants with CHD Lifetime 3% None 

BC, base case; CBA, cost-benefit analysis; CEA, cost-effectiveness analysis; CUA, cost-utility analysis; NR, not reported; N/A, not applicable.

a

Not clearly reported; assumed on the basis of data used for cohorts.

b

Four percent for economic outcomes and 1.5% for clinical outcomes.

Close Modal

or Create an Account

Close Modal
Close Modal